Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Rating of "Buy" from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) have earned an average rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $22.43.

A number of research analysts have recently commented on CLBT shares. JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Lake Street Capital increased their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Finally, Needham & Company LLC lowered their target price on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bosun Asset Management LLC grew its holdings in Cellebrite DI by 1.4% during the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after acquiring an additional 584 shares during the period. OneDigital Investment Advisors LLC grew its holdings in Cellebrite DI by 2.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after acquiring an additional 688 shares during the period. TD Waterhouse Canada Inc. grew its holdings in Cellebrite DI by 1.8% during the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after acquiring an additional 859 shares during the period. Strategic Advisors LLC grew its holdings in Cellebrite DI by 3.4% during the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock worth $641,000 after acquiring an additional 950 shares during the period. Finally, Advisors Asset Management Inc. grew its holdings in Cellebrite DI by 24.7% during the 1st quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock worth $119,000 after acquiring an additional 1,214 shares during the period. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Stock Performance

Shares of CLBT opened at $16.84 on Friday. Cellebrite DI has a 52 week low of $10.42 and a 52 week high of $26.30. The stock has a market capitalization of $4.03 billion, a price-to-earnings ratio of -12.12, a PEG ratio of 4.27 and a beta of 1.32. The stock has a fifty day moving average of $18.41 and a 200-day moving average of $20.09.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The company had revenue of $107.55 million during the quarter, compared to analysts' expectations of $109.36 million. During the same period in the prior year, the company earned $0.08 EPS. Cellebrite DI's revenue was up 20.0% compared to the same quarter last year. As a group, equities analysts forecast that Cellebrite DI will post 0.3 EPS for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.